The product which is interventive, minimally invasive, without surgical sutures and cardiopulmonary bypass is used to replace the diseased mitral valve. This new designed product can simplify the replacement surgery, significantly reducing the risks of treatment and increasing success rate. Moreover, this can shorten patients’ postoperative recovery time and cut down costs. Furthermore, reduced price of similar products enables more patients to have opportunities to endure risk and expense of surgery and treatment. As a revolutionary treatment, transcatheter artificial heart valve prosthesis is being well recognized by experts. In the future, clinical demands will grow explosively.